Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
17 studies found for:    ac-220
Show Display Options
Rank Status Study
1 Completed Dose Finding, Safety and Tolerability Study for AC220 to Treat Advanced Solid Tumors
Condition: Solid Tumors
Intervention: Drug: Compound AC220
2 Completed Efficacy Study for AC220 to Treat Acute Myeloid Leukemia (AML)
Condition: Acute Myeloid Leukemia
Intervention: Drug: Compound AC220
3 Completed A Phase I Study of AC220 in Patients With Relapsed/Refractory Acute Myeloid Leukemia Regardless of FLT3 Status
Conditions: Acute Myeloid Leukemia;   Leukemia;   Myelodysplastic Syndrome;   AML;   MDS
Intervention: Drug: AC220
4 Completed A Study of AC220 Given After Transplant in Subjects With Acute Myeloid Leukemia (AML)
Condition: Leukemia, Myeloid, Acute
Intervention: Drug: AC220
5 Completed A Phase I Study of AC220 for Children With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia
Conditions: Lymphoblastic Leukemia, Acute, Childhood;   Myelogenous Leukemia, Acute, Childhood
Interventions: Drug: AC220;   Drug: Cytarabine;   Drug: Etoposide;   Drug: Methotrexate
6 Completed A Study to Assess AC220 Given in Combination With Induction and Consolidation Therapy in Newly Diagnosed Acute Myeloid Leukemia (AML)
Condition: Leukemia, Myeloid, Acute
Interventions: Drug: AC220;   Drug: daunorubicin;   Drug: cytarabine
7 Completed A Trial to Establish the Feasibility of Combining Either the Tyrosine Kinase Inhibitor AC220,CXCR4 Inhibitor Plerixafor or HSP90 Inhibitor Ganetespib With Chemotherapy in Older Patients With Acute Myeloid Leukaemia and High Risk Myelodysplastic Syndrome.
Conditions: Acute Myeloid Leukaemia;   High Risk Myelodysplastic Syndrome
Interventions: Drug: Plerixafor;   Drug: AC220;   Drug: Ganetespib
8 Recruiting AC220 With 5-Aza or Low Dose Cytarabine
Condition: Leukemia
Interventions: Drug: Quizartinib;   Drug: Cytarabine;   Drug: AZA
9 Completed Open Label Study to Evaluate Safety and Efficacy of 2 Doses of Quizartinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Condition: Leukemia, Myeloid, Acute
Intervention: Drug: AC220
10 Recruiting Phase 1 Study of Quizartinib
Conditions: Relapsed AML;   Refractory AML
Intervention: Drug: AC220
11 Recruiting (QuANTUM-R): An Open-label Study of Quizartinib Monotherapy vs. Salvage Chemotherapy in Acute Myeloid Leukemia (AML) Subjects Who Are FLT3-ITD Positive
Condition: AML
Interventions: Drug: Quizartinib;   Drug: Salvage Chemotherapy
12 Recruiting Quizartinib With Standard of Care Chemotherapy and as Maintenance Therapy in Patients With Newly Diagnosed FLT3-ITD (+) AML
Conditions: Acute Myeloid Leukemia;   Leukemia
Interventions: Drug: Cytarabine;   Drug: Daunorubicin;   Drug: Idarubicin;   Drug: Quizartinib;   Drug: Placebo
13 Not yet recruiting Phase 2 Study of Quizartinib in Participants With Acute Myeloid Leukemia (AML) FLT3 Internal Tandem Duplication (FLT3/ITD) Mutation
Condition: Leukemia, Myeloid, Acute
Intervention: Drug: Quizartinib
14 Recruiting Trial to Test the Effects of Adding 1 of 2 New Treatment Agents to Commonly Used Chemotherapy Combinations
Conditions: Acute Myeloid Leukaemia;   Myelodysplastic Syndrome
Interventions: Drug: Arm A Mylotarg;   Drug: Arm D Cladribine;   Drug: AC220;   Drug: Ganetespib
15 Completed Developing and Treating a Mouse Model of Acute Myeloid Leukemia Using Tissue Samples From Younger Patients With Acute Myeloid Leukemia
Condition: Childhood Acute Myeloid Leukemia/Other Myeloid Malignancies
Interventions: Other: laboratory biomarker analysis;   Drug: quizartinib;   Drug: sorafenib tosylate
16 Recruiting Ponatinib for FLT3-ITD Acute Myelogenous Leukemia
Condition: Acute Myeloid Lukemia
Intervention: Drug: Ponatinib and Cytarabine
17 Recruiting Study of Quizartinib in Japanese Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
Condition: Acute Myeloid Leukemia
Interventions: Drug: quizartinib;   Drug: Cytarabine;   Drug: Idarubicin;   Drug: Daunorubicin

Study has passed its completion date and status has not been verified in more than two years.